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TabletsAbstract Thermogravimetry and differential scanning calorimetry (DSC) are useful techniques
that have been successfully applied in the pharmaceutical industry to reveal important information
regarding the physicochemical properties of drug and excipient molecules such as stability, purity
and formulation compatibility among others. The present work reports studies of the thermal
behavior of antihypertensive drug doxazosin mesilate as raw material and in the form of tablets.
The purity was determined by DSC and specialized pharmacopeial method. Analysis of the DSC
data indicated that the degree of purity of doxazosin mesilate was similar to that found by the ofﬁ-
cial HPLC method used in the British pharmacopoeia, BP 2011. The simplicity and sensitivity of
thermal analysis justify its application in the quality control of pharmaceutical compounds.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Thermogravimetry is an analytical, quantitative and compara-
tive method, capable of producing fast and reproducible
results. It can be used in the quality control of drugs, with a
view to improvement of the ﬁnal product and for the determi-
nation of drug quality via the technological parameters.
Differential scanning calorimetry (DSC) can be used in the
pharmaceutical industry as an analytical tool of great impor-
tance for the identiﬁcation and purity testing of active drugs,
yielding results rapidly and efﬁciently. DSC has been appliedfor the quality control of raw materials used in pharmaceutical
products. Several reports in the literature demonstrate the
importance of thermal analysis by thermal gravimetric analysis
(TGA), derivative thermogravimetry (DTG), differential ther-
mal analysis (DTA) and differential scanning calorimetry
(DSC) in the characterization, polymorphism identiﬁcation,
and purity evaluation of drugs (Caira et al., 2004; Craig and
Reading, 2007; El-Ries et al., 2011; Freitas et al., 2007;
Gabbott, 2008; Macedo et al., 2002; Oliveira et al., 2005;
Radha et al., 2010; Stulzer et al., 2008; Wassel, 2011; El-Ries
et al., 2010; Attia et al., 2012).
Doxazosin mesilate (Fig. 1) is an alpha1-adrenoceptor
blocker with actions and uses similar to those of prazosin,
but a longer duration of action. It is used in the management
of hypertension and in benign prostatic hyperplasia to relieve
symptoms of urinary obstruction (Sweetman, 2009).
Several methods have been reported on the determination
of doxazosin mesilate, including the use of HPLC for its deter-
mination in the plasma and pharmaceutical formulations
Figure 1 Chemical structure of doxazosin mesilate.
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et al., 2010), differential pulse polarography (Ozgur et al.,
1997; Altiokkia and Tuncel, 1998), cathodic stripping voltame-
try (Arranz et al., 1997), adsorptive stripping voltametry (De
Betono et al., 1996) and stability indicating methods (Bebawy
et al., 2002).2. Experimental
2.1. Materials
Doxazosin mesilate, raw material and Doxacor tablets were
provided from the Minapharm Pharmaceuticals and Chemical
Industries, Cairo, Egypt. The purity of doxazosin mesilate was
found to be 99.80% according to the British pharmacopoeia,
BP 2011.
2.2. Methods
Thermal analysis studies were made by using simultaneous
TGA–DTA thermal analyzer apparatus (Shimadzu DTG-
60H). The experiments were performed between ambient and
800 C. The temperature program had a heating rate of
10 C/min. Dry nitrogen at a low rate of 30 ml/min was used
as the purge gas. a-Al2O3 was used as the reference material.
DSC curves were measured on Shimadzu DSC-50 cell.
Approximately 2 mg of samples was massed out and placed
in a sealed aluminum pan. An empty aluminum pan was used
as a reference. The purity determination was performed using
a heating rate of 10 C/min in the temperature range of 25–
400 C in nitrogen atmosphere with a ﬂow rate of 30 ml/min.
DSC equipment was preliminary calibrated with a standard
of indium.3. Results and discussion
3.1. Thermal analysis behavior of doxazosin mesilate
Fig. 2 indicates that the thermal decomposition of doxazosin
mesilate occurs in three consecutive steps. The ﬁrst step shows
the loss of 28.31% in the temperature range of 240–365 C due
to the elimination of the substituent groups dimethoxy and
methanesulfonate groups, the second step shows the loss of
24.78% in the temperature range of 365–457 C due to the
elimination of the C8H7O2 molecule, the third step shows the
loss of 46.54% in the temperature range of 457–800 C due
to the elimination of C13H12N5O group and the complete
decomposition of the compound.The DTA curve in Fig. 2 shows that the doxazosin mesilate
has an endothermic peak and three exothermic peaks. The
endothermic reaction peak which is not accompanied by
weight loss occurs at 273 C. This reaction may be attributed
to the melting of the compound. Three exothermic peaks; an
exothermic peak with its maximum at 325 C may be attrib-
uted to the loss of dimethoxy and methanesulfonate groups,
an exothermic peak at 455 C as a shoulder may be attributed
to loss of C8H7O2 molecule and strong exothermic peak at
488 C which may be attributed to loss of C13H12N5O and
complete decomposition of the compound.
3.2. Determination of purity of doxazosin mesilate
An important concern of analytical chemistry is the determina-
tion of purity of organic compounds. Most techniques that are
currently being employed in instrumental analysis involve the
analysis of a given sample in comparison with a standard sam-
ple. Advances in analytical instrumentation require an extre-
mely high degree of purity warranty for standard samples,
the determination of purity is thus important not only for lab-
oratory use, but also for a broad spectrum of applications in
which the quality warranty of reagent and drugs is vitally
important. There is an increasing need for more accurate deter-
mination methods that are easy to use.
Thermal methods are easy to use, can be performed quickly
and are effective in measuring unknown impurities. On the
other hand, DSC may be a simple and rapid method of esti-
mating the purity of materials. However, its use has been lim-
ited to a substance of rather high purity. The minimum purity
required for this method is approximately 98%. Therefore, the
DSC method is rarely used by itself to warrant purity. For this
reason, traditionally chromatographic techniques such as
HPLC and GC are used for purity measurement (Mathkar
et al., 2009).
The determination of purity is based on the assumption
that impurities lower the melting point of a pure substance.
The melting transition of a pure, 100% crystalline substance
should be inﬁnitely sharp, but impurities or defects in the crys-
tal structure will broaden the melting range and lower the
melting point (Hatakeyama and Liu, 1998). In a system which
contains impurities, Van’t Hoff equation approximately holds
and allows the purity value to be calculated as follows:
Tf ¼ T0  ½ðRT20 X=DHfÞ: 1=F
where Tf is the melting temperature of the sample, T0 is the
melting point of pure substance in Kelvin (K), R is the gas con-
stant, DHf is the heat of fusion, F is the fraction melted and X
is the mole fraction of impurities.
Figure 2 TGA, DTG and DTA curves of doxazosin mesilate.
Figure 3 DSC curves of doxazosin mesilate (a) and doxacor tablets (b).
S336 A.K. Attia et al.Fig. 3 shows the DSC curve for doxazosin mesilate indicat-
ing an endothermic reaction with a sharp peak at 275 C
related to the melting point of the drug and another exother-
mic peak at 325 C. The sample seems to be suitable for purity
determination by the DSC method, the drug was found to be
very pure (99.97%). As shown in Table 1 the purity of the drug
was compared with that obtained by using the ofﬁcial method
(99.80%) conﬁrming low impurity content and also Table 1Table 1 Melting point and degree of purity of doxazosin mesilate.
Melting point (C)
DTA method Melting point apparatusa DSC method
273 276 275
a Mettler FP 80.
b Clark’s analysis of drugs and poisons (Anthony et al., 2004).
c British pharmacopoeia (2011).showed satisfactory results for the melting point of the used
drug by using different methods.
3.3. Quality control application of doxazosin mesilate
Thermal analysis is used as an alternative technique for the
determination of different quality parameters such as waterDegree of purity (%)
Literatureb DSC method Oﬃcial methodc
275–277 99.97% 99.80%
Table 2 Quality control parameters obtained from the thermal analysis of doxazosin mesilate compared with reported method.
Water content (%) Ash content (%)
Thermal analysis method Reported methoda Thermal analysis method Reported methoda
0.38 0.65 (Max. 1.5%) Zero 0.05 (Max. 0.1%)
a British pharmacopoeia (2011).
Figure 4 TGA, DTG and DTA curves of doxacor tablets.
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between the obtained results when compared with the reported
method as shown in Table 2.
3.4. Thermal analysis application of doxacor tablets
TGA, DTG and DTA of doxacor tablets curves were presented
in Fig. 4. The DTA of doxacor tablets indicates the melting of
doxazosin mesilate at 212 C. It was observed that the drug
melting event occurs with mass loss; the onset and the end set
temperatures of the DTA curve of the doxacor tablets were
shifted to lower temperatures than that of the DTA curve of
doxazosin mesilate. In fact a similar effect was observed forFigure 5 DTA curves of doxacor tablets (a), microcrystalline
cellulose (b), magnesium stearate (c) and povidone (d).other drug excipients mixtures and was attributed to drug dis-
solution in the melted excipients (Cides et al., 2006).
Fig. 5 shows the DTA curves of these excipients and doxa-
cor tablets. The excipients can produce a different environment
in which the behavior of the drug is modiﬁed but they are still
compatible with the drug. Based on the results of DTA curves,
majority of the excipients such as Mg stearate, povidone and
microcrystalline cellulose were found to be compatible with
the drug.
DSC curve of doxacor tablets (Fig. 3) shows a sharp endo-
thermic peak at 208.22 C corresponding to the melting point
of doxazosin mesilate. By comparing the melting point values
of the pure drug shown in Table 1 with those obtained for dox-
azosin mesilate in doxacor tablets we found that the melting
point values of the pure drug are higher than those in tablets
due to the presence of excipients.
4. Conclusion
Solid state reactions include phase transitions such as melting,
evaporation and sublimation, as well as decomposition reac-
tions resulting in the production of different compounds. Ther-
mal analysis can be used to monitor these reactions by
determining the rate of mass loss as the sample undergoes
the process. Thermal analysis methods are widely used in all
ﬁelds of pharmaceutical sciences but especially in pre-formula-
tion studies. These techniques are unique for the characteriza-
tion of compounds and mixtures. The excipients can produce a
different environment in which the behavior of the drug is
modiﬁed but they are still compatible with the drug. Thermal
analysis can be used in quality control of pharmaceutical com-
pounds. DSC data indicated that the degree of purity of dox-
azosin mesilate is similar to that found by the ofﬁcial method.
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